Navigation Links
Quanterix Announces Strategic Investment From IQT
Date:1/5/2012

CAMBRIDGE, Mass., Jan. 5, 2012 /PRNewswire/ -- Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array (SiMoA™) technology, announced today a strategic investment and technology development agreement with In-Q-Tel (IQT), the independent strategic investment firm that identifies innovative technology solutions to support the missions of the U.S. Intelligence Community.  Through this strategic partnership, Quanterix aims to expand the development of its SiMoA technology to enable simultaneous measurement of both nucleic acids and proteins for the detection of pathogens.

Quanterix is developing and manufacturing a fully-automated instrument and low cost consumables for use in both the life sciences and in vitro diagnostics (IVD) markets. SiMoA, which has been validated in multiple published journal articles, will facilitate direct and non-amplified detection of pathogens to obtain a level of sensitivity that could previously only be achieved with amplification methods.  

"The ability to accurately detect the presence of low abundance molecules makes Quanterix technology a critical addition to our strategic investment portfolio," stated Syd Ulvick, Ph.D., Vice President, Physical and Biological Technologies practice at IQT.  "The Quanterix SiMoA platform offers great promise for applications in both the private and public sectors." 

"We are delighted to have In-Q-Tel as a strategic investor and partner, and view this investment as a validation of our technological capabilities," said Martin Madaus, Ph.D., Quanterix Chairman and CEO.  "We are excited to initiate this partnership to expand our platform capabilities to include novel applications that address the needs of the Intelligence Community."  

About Quanterix

Quanterix Corporation is developing its proprietary Single Molecule Array (SiMoA™) technology for the in vitro diagnostics and life science research markets. The digital nature of SiMoA yields unprecedented assay performance, stemming from a 1,000-fold improvement in sensitivity compared with today's analog only technology. SiMoA will enable researchers in life science to validate novel, low abundance biomolecules from a single droplet of blood, leading to greater insight into disease detection, diagnosis, therapy selection and disease monitoring. Automated systems based on SiMoA will provide diagnostic test information to healthcare practitioners faster, with greater reliability, unprecedented range and increased cost effectiveness.  Founded in 2007, the privately held Cambridge, Massachusetts-based company is backed by leading life science investors including ARCH Venture Partners, Bain Capital Ventures, and Flagship Ventures. For additional information, please visit www.quanterix.com.

About IQT

In-Q-Tel is the not-for-profit, strategic investment firm that works to identify, adapt, and deliver innovative technology solutions to support the missions of the U.S. Intelligence Community. Launched in 1999 as a private, independent organization, IQT's mission is to identify and partner with companies developing cutting-edge technologies that serve the national security interests of the United States. Working from an evolving strategic blueprint defining the Intelligence Community's critical technology needs, IQT engages with entrepreneurs, startups, researchers, and investors to deliver technologies that provide superior capabilities for the CIA and broader Intelligence Community. For more information, visit www.iqt.org.


'/>"/>
SOURCE Quanterix Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Quanterix Digital Immunoassay for Prostate Specific Antigen Improves Analytical Performance
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
Breaking Medicine News(10 mins):